AstraZeneca PLC (AZN)
| Market Cap | 265.89B |
| Revenue (ttm) | 56.50B |
| Net Income (ttm) | 8.30B |
| Shares Out | 1.55B |
| EPS (ttm) | 5.31 |
| PE Ratio | 16.17 |
| Forward PE | 17.67 |
| Dividend | $1.54 (1.79%) |
| Ex-Dividend Date | Aug 8, 2025 |
| Volume | 1,147,534 |
| Open | 85.42 |
| Previous Close | 85.49 |
| Day's Range | 85.35 - 86.06 |
| 52-Week Range | 61.24 - 86.57 |
| Beta | 0.17 |
| Analysts | Strong Buy |
| Price Target | n/a |
| Earnings Date | Nov 11, 2025 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsNews
Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in a...
AstraZeneca's Baxdrostat meets main goal in high blood pressure study
AstraZeneca said on Tuesday its drug Baxdrostat met the main goal in a late-stage study in patients with treatment-resistant high blood pressure, or hypertension.
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
AstraZeneca signs up to $555 million deal with US-based Algen to develop gene therapies
Algen Biotechnologies said on Monday it has agreed to grant AstraZeneca a license to develop gene therapies the U.S.-based biotech discovers using its artificial intelligence-driven platform, in a dea...
Algen Biotechnologies Announces Multi-Target Partnership to Advance AI-Powered Drug Discovery in Immunology with AstraZeneca
SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Algen Biotechnologies Announces Multi-Target Partnership to Advance AI-Powered Drug Discovery in Immunology with AstraZeneca.
AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports
AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday.
AstraZeneca's Datroway boosts survival in advanced breast cancer trial
AstraZeneca said on Monday its precision drug Datroway improved overall survival and progression free survival in patients with an advanced form of breast cancer versus chemotherapy in a trial when gi...
Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated
Drug stocks are poised to outperform in 2025, driven by conservative valuations and a research renaissance in key therapeutic areas. US healthcare spending growth and transformative GLP-1 therapies, e...
AstraZeneca shares leap with FDA set to review drug to treat breast cancer
AstraZeneca shares rallied on Wednesday after the U.K. giant and its Japanese partner said the Food and Drug Administration was reviewing one of its drugs to treat breast cancer.
CNBC's UK Exchange newsletter: AstraZeneca gets a shot on Wall Street
AstraZeneca is delisting its American Depositary Receipts from the Nasdaq, replacing them with a direct listing of ordinary shares on the New York Stock Exchange. At first blush, it confirms fears fir...
AstraZeneca's US listing may pull other firms from London in its wake
AstraZeneca's move to upgrade its listing in the U.S. risks pulling liquidity away from London's stock market and could pave the way for other large companies to follow suit, analysts, investors and a...
AstraZeneca plans to list on NYSE, but will remain in the U.K.
AstraZeneca laid out plans on Monday to switch to a direct listing of its shares in the United States, as the drugmaker seeks to maximise gains from a booming U.S. stock market, even as it said it was...
Pharma giant AstraZeneca eyes NYSE listing overhaul, keeps London base
AstraZeneca announced plans to change how it lists shares in the United States by moving from American depositary receipts (ADRs) on Nasdaq to a direct listing of its ordinary shares on the New York S...
AstraZeneca to directly list shares in New York, retain UK listing
AstraZeneca said on Monday that it will now directly list its shares on the New York Stock Exchange, instead of the current depository shares, adding that it will continue to be listed and headquarter...
Pharma tariffs 'not a huge risk' for domestic companies, says Mizuho's Jared Holz
CNBC's “Fast Money” team discusses the potential impact of pharmaceutical tariffs with Jared Holz, healthcare equity strategist at Mizuho.
A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff
Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products pu...
AstraZeneca to Offer Discounted Drugs As Trump Pressures Pharma Industry to Cut Prices
AstraZeneca said it will offer its asthma and diabetes drugs at an up to 70% discount in the U.S. ahead of a Trump administration deadline for pharmaceutical companies to cut drug prices.
AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their pr...
AstraZeneca to cut some direct-to-patient US drug prices after Trump demand
AstraZeneca said on Friday it will sell its diabetes and asthma drugs direct to cash-paying U.S. patients at a discount of up to 70% off list prices, the latest pharma company to do so after pressure ...
AstraZeneca: Oncology Breakthroughs And Farxiga Surge Excite Investors
Even with Trump's looming threats to impose tariffs on pharma imports, the performance of AstraZeneca's cardiovascular and oncology franchises continues to impress me. So, sales of Truqap, which conti...
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has ...
European Advisory Panel Recommends Two AstraZeneca Drugs For Approval
AstraZeneca Plc AZN and Amgen Inc.'s AMGN Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
BOSTON , Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LS...
Bloomberg Dividend Watchlist's 4 Ideal 'Safer' September Sizzlers
Bloomberg Intelligence highlights 50 Companies to Watch for 2025, focusing on catalysts like leadership changes, M&A, and sector trends such as AI and EVs. Dogcatcher analysis identifies 13 dividend-p...
3 Potential Biotech Acquisition Targets
There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have go...